Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

6 Months Ended

Jun. 30, 2022

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

13.	Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except share and per share amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Net loss attributable to Adaptive Biotechnologies Corporation	$	(52,046	)	$	(49,301	)	$	(114,782	)	$	(89,943	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		142,363,589			140,359,317			142,032,261			139,667,380
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.37	)	$	(0.35	)	$	(0.81	)	$	(0.64	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2022 and 2021, respectively, as they had an anti-dilutive effect:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Stock options outstanding		14,693,276		13,204,775		13,978,339		13,360,000
Nonvested restricted stock units		5,364,447		676,411		3,983,640		458,707
Maximum nonvested market-based restricted stock units eligible to be earned		494,234		—		324,938		—
Common stock warrant outstanding		—		—		—		17,282
Total		20,551,957		13,881,186		18,286,917		13,835,989